Linked Life Data

14662856

Source:http://linkedlifedata.com/resource/pubmed/id/14662856

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2003-12-9
pubmed:abstractText
Inflammation plays an important role in ischemic stroke and in humans IL-10 may have a beneficial effect in stroke. We mucosally administered myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide to C57BL/6 mice before middle cerebral artery occlusion (MCAO) to induce an anti-inflammatory T cell response directed at CNS myelin. Nasal and oral administration of MOG(35-55) peptide decreased ischemic infarct size at 24 and 72 h after MCAO surgery. Nasal MOG(35-55) peptide was most efficacious and reduced infarct size by 70% at 24 h and by 50% at 72 h (p <or= 0.0001 vs control) and also improved behavior score. Immunohistochemistry demonstrated increased IL-10 and reduced IFN-gamma in the area surrounding the ischemic infarct following nasal treatment. Nasal MOG did not reduce infarct size in IL-10-deficient mice. Adoptive transfer of CD4(+) T cells to untreated mice from nasally tolerized mice before MCAO surgery decreased stroke size (p < 0.001 vs control), whereas, CD4(+) T cells from nasally tolerized IL-10-deficient mice had no effect. Our results demonstrate that IL-10-secreting CD4(+) T cells induced by nasal MOG reduce injury following stroke. In addition, we observed a dramatic reduction of CD11b(+) cells in nasal MOG-treated animals. CD11b(+) cells may contribute to secondary infarct expansion by enhancing NO synthesis that may be reduced by elevated IL-10 levels. Modulation of cerebral inflammation by nasal vaccination with myelin Ags that increase IL-10 in the brain may improve outcome after stroke and enhance mechanisms of recovery.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
171
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6549-55
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:14662856-Administration, Intranasal, pubmed-meshheading:14662856-Administration, Oral, pubmed-meshheading:14662856-Adoptive Transfer, pubmed-meshheading:14662856-Animals, pubmed-meshheading:14662856-Brain Ischemia, pubmed-meshheading:14662856-CD4-Positive T-Lymphocytes, pubmed-meshheading:14662856-Cytokines, pubmed-meshheading:14662856-Disease Models, Animal, pubmed-meshheading:14662856-Female, pubmed-meshheading:14662856-Glycoproteins, pubmed-meshheading:14662856-Immune Tolerance, pubmed-meshheading:14662856-Immunity, Mucosal, pubmed-meshheading:14662856-Immunohistochemistry, pubmed-meshheading:14662856-Infarction, Middle Cerebral Artery, pubmed-meshheading:14662856-Interleukin-10, pubmed-meshheading:14662856-Mice, pubmed-meshheading:14662856-Mice, Inbred C57BL, pubmed-meshheading:14662856-Mice, Knockout, pubmed-meshheading:14662856-Neuroprotective Agents, pubmed-meshheading:14662856-Peptide Fragments, pubmed-meshheading:14662856-Vaccines
pubmed:year
2003
pubmed:articleTitle
Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells.
pubmed:affiliation
Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't